STOCK TITAN

Flushing Financial Corporation Celebrates its 30th Anniversary of being Listed on Nasdaq

(Neutral)
Tags

Neurocrine Biosciences (Nasdaq: NBIX) reported Phase 2 SAVITRI results showing that once-daily 1 mg osavampator produced statistically significant and clinically meaningful reductions in depression severity at Day 28 and Day 56 versus placebo in adults with major depressive disorder with inadequate response to antidepressants. The randomized 2:1:1 study enrolled 183 adults. Osavampator was generally well tolerated with no serious adverse events; common TEAEs included headache and nasopharyngitis. An exploratory exposure-response analysis supports continuing 1 mg into planned Phase 3 studies.

Loading...
Loading translation...

Positive

  • Primary endpoint met: significant MADRS reduction at Day 28
  • Durable effect: 1 mg maintained significance at Day 56
  • Support for Phase 3: exposure-response analysis favors 1 mg
  • No serious AEs reported: safety profile acceptable in study

Negative

  • Higher any-TEAE rate: 1 mg 55.6% vs placebo 42.9%
  • 3 mg underperformed: 3 mg did not achieve consistent statistical significance
  • Small sample size: total N=183 may limit generalizability

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNIONDALE, NY / ACCESS Newswire / November 18, 2025 / Flushing Financial Corporation (the "Company") (Nasdaq:FFIC), the parent holding company for Flushing Bank (the "Bank"), announced today that President and CEO John Buran, members of the Company's Board of Directors and senior management will ring the Nasdaq Stock Market Closing Bell to commemorate the 30th anniversary of its Nasdaq listing on Tuesday, November 18, 2025.

John Buran stated, "It's a tremendous honor to be here at Nasdaq MarketSite as we celebrate 30 years as a Nasdaq-listed company and nearly a century as a community bank. This milestone reflects the dedication of our people and our commitment to building rewarding relationships and expanding our banking services to individuals, families and businesses. As we look ahead, our focus remains clear: to deliver long-term value, support economic growth in the communities we serve, and build a stronger future together."

The Nasdaq Closing Bell ceremony will take place at Nasdaq MarketSite in Times Square, New York, beginning at approximately 3:45 PM ET on November 18, 2025. The ceremony can be viewed live at https://www.nasdaq.com/marketsite/bell-ringing-ceremony.

About Flushing Financial Corporation

Flushing Financial Corporation (Nasdaq:FFIC) is the holding company for Flushing Bank®, an FDIC insured, New York State-chartered commercial bank that operates banking offices in Queens, Brooklyn, Manhattan, and on Long Island. The Bank has been building relationships with families, business owners, and communities since 1929. Today, it offers the products, services, and conveniences associated with large commercial banks, including a full complement of deposit, loan, equipment finance, and cash management services. Rewarding customers with personalized attention through bankers who can communicate in the languages prevalent within these multicultural markets are what makes the Bank uniquely different. As an Equal Housing Lender and leader in real estate lending, the Bank's experienced lending teams create mortgage solutions for real estate owners and property managers both within and outside the New York City metropolitan area. The Bank also fosters relationships with consumers nationwide through its online banking division with the iGObanking® and BankPurely® brands.

Additional information on Flushing Bank and Flushing Financial Corporation may be obtained by visiting the Company's website at FlushingBank.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this Press Release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in other documents filed by the Company with the Securities and Exchange Commission from time to time. Forward-looking statements may be identified by terms such as "may", "will", "should", "could", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "forecasts", "goals", "potential" or "continue" or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward- looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. The Company has no obligation to update these forward-looking statements.

#FB

Contact:

Maria A. Grasso
Senior Executive Vice President, Chief Operating Officer
Flushing Bank
718-961-5400

SOURCE: Flushing Financial Corporation



View the original press release on ACCESS Newswire

FAQ

What did Neurocrine announce about osavampator (NBIX) on November 18, 2025?

Neurocrine announced Phase 2 SAVITRI results showing 1 mg osavampator produced significant MADRS improvements at Day 28 and Day 56 and will be advanced to Phase 3 evaluation.

How many patients and what design were used in the Phase 2 SAVITRI study for NBIX?

The study randomized 183 adults aged 18–65 in a 2:1:1 ratio to placebo, osavampator 1 mg, or 3 mg once daily for eight weeks.

What efficacy outcomes did osavampator 1 mg achieve in the SAVITRI study?

Osavampator 1 mg met the primary endpoint (MADRS reduction at Day 28) and showed statistically significant response and remission improvements by Day 56 versus placebo.

What safety findings were reported for osavampator in the Phase 2 SAVITRI study?

No serious adverse events or adverse events of special interest were reported; common TEAEs included headache and nasopharyngitis, with any-TEAE rates of 55.6% for 1 mg versus 42.9% for placebo.

Why is Neurocrine prioritizing the 1 mg dose of osavampator for Phase 3?

An exploratory post hoc exposure-response analysis substantiated continued evaluation of the 1 mg once-daily dosing in planned Phase 3 studies.